Endosulfan and flutamide, alone and in combination, target ovarian growth in juvenile catfish, Clarias batrachus.
Juvenile Catfish(es), Clarias batrachus of 50 days post hatch (dph) were exposed to endosulfan (2.5 parts per billion [ppb]) and flutamide (33 ppb), alone and in combination for 50 days to access their impact on ovarian development. The doses used in this study were nominal considering pervious reports. Sampling was done at 100 dph to perform histology and measurement of various transcripts, estradiol-17β and aromatase activity. In general, treatments enhanced expression of ovary-specific transcription factors, steroidogenic enzymes steroidogenic acute regulatory protein and aromatases while transcripts of tryptophan hydroxylase2 (tph2) and catfish gonadotropin-releasing hormone declined in the brain of all treated groups with maximum reduction in the endosulfan group. Significant reduction of tph2 immunoreactivity in the forebrain/telencephalon-preoptic area endorsed our results. Increased number of pre-vitellogenic and less immature oocytes in the treated groups indicated hastened ovarian growth. Elevated ovarian aromatase activity and plasma estradiol-17β levels were noticed in the treated groups with maximum being in the endosulfan group. These data together demonstrate that the exposure of endosulfan causes synchronous precocious ovarian development better than flutamide, alone or in combination. Our results suggest that both endosulfan and flutamide alter ovarian growth by triggering precocious development in catfish.
Department of Animal Sciences, School of Life Sciences-Centre for Advanced Studies, University of Hyderabad, P. O. Central University, Hyderabad - 500 046, Andhra Pradesh, India.
S
S
Chakrabarty
A
A
Rajakumar
K
K
Raghuveer
P
P
Sridevi
A
A
Mohanachary
Y
Y
Prathibha
L
L
Bashyam
A
A
Dutta-Gupta
B
B
Senthilkumaran
D000818:Animals; D001141:Aromatase / Q000378:metabolism; D002397:Catfishes / Q000235:genetics / Q000378:metabolism*; D004338:Drug Combinations; D004726:Endosulfan / Q000009:adverse effects* / Q000378:metabolism; D004958:Estradiol / Q000378:metabolism; D005260:Female; D005485:Flutamide / Q000009:adverse effects* / Q000378:metabolism; D005786:Gene Expression Regulation; D007987:Gonadotropin-Releasing Hormone / Q000235:genetics / Q000378:metabolism; D007150:Immunohistochemistry; D009865:Oocytes / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism; D010053:Ovary / Q000187:drug effects* / Q000254:growth & development / Q000473:pathology; D055758:SOX9 Transcription Factor / Q000235:genetics / Q000378:metabolism; D013687:Telencephalon / Q000187:drug effects / Q000378:metabolism; D014365:Tryptophan Hydroxylase / Q000235:genetics / Q000378:metabolism
D004338:Drug Combinations; D055758:SOX9 Transcription Factor; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D005485:Flutamide; D001141:Aromatase; D014365:Tryptophan Hydroxylase; D004726:Endosulfan